SDF-1 and its receptor in the ventricles of rat with monocrotaline-induced pulmonary hypertension

European Pharmaceutical Journal Pub Date : 2018-11-01 DOI:10.2478/afpuc-2018-0004

J. Vetešková, M. Obsivan, Z. Kmecová, M. Radik, J. Srankova, E. Malikova, Jan Klimas, P. Krenek

{"title":"SDF-1 and its receptor in the ventricles of rat with monocrotaline-induced pulmonary hypertension","authors":"J. Vetešková, M. Obsivan, Z. Kmecová, M. Radik, J. Srankova, E. Malikova, Jan Klimas, P. Krenek","doi":"10.2478/afpuc-2018-0004","DOIUrl":null,"url":null,"abstract":"Abstract Aim: Chemokine stromal cell derived factor-1 (SDF-1) plays an important role in many processes such as apoptosis, proliferation, migration and angiogenesis, and these effects are mediated mostly by the receptor CXCR4. The aim of this study was to determine the expression of SDF-1 and CXCR4 in the ventricles of rats with monocrotaline-induced pulmonary hypertension. Methods: 10–12 weeks old male Wistar rats were injected with monocrotaline (s. c., 60mg/kg; MON) or vehicle (CON). Rats were sacrificed 1 week (1W-MON, 1W-CON), 2 weeks (2W-MON, 2W-CON) and 4 weeks after monocrotaline administration (4W-MON, 4W-CON). Gene expression of SDF-1 and CXCR4 was determined by qRT-PCR. Results: We observed a decrease in the SDF-1 expression on mRNA level in the right ventricle in 2W-MON and 4W-MON rats without any changes in the left ventricles and a decrease in CXCR4 expression in 1W-MON in both ventricles with an increase of CXCR4 expression in 4W-MON in the left ventricle (*P ˂ 0.05). Conclusion: SDF-1/CXCR4 axis is affected in both ventricles of rats with monocrotaline model of pulmonary hypertension.","PeriodicalId":12070,"journal":{"name":"European Pharmaceutical Journal","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2018-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Pharmaceutical Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2478/afpuc-2018-0004","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Abstract Aim: Chemokine stromal cell derived factor-1 (SDF-1) plays an important role in many processes such as apoptosis, proliferation, migration and angiogenesis, and these effects are mediated mostly by the receptor CXCR4. The aim of this study was to determine the expression of SDF-1 and CXCR4 in the ventricles of rats with monocrotaline-induced pulmonary hypertension. Methods: 10–12 weeks old male Wistar rats were injected with monocrotaline (s. c., 60mg/kg; MON) or vehicle (CON). Rats were sacrificed 1 week (1W-MON, 1W-CON), 2 weeks (2W-MON, 2W-CON) and 4 weeks after monocrotaline administration (4W-MON, 4W-CON). Gene expression of SDF-1 and CXCR4 was determined by qRT-PCR. Results: We observed a decrease in the SDF-1 expression on mRNA level in the right ventricle in 2W-MON and 4W-MON rats without any changes in the left ventricles and a decrease in CXCR4 expression in 1W-MON in both ventricles with an increase of CXCR4 expression in 4W-MON in the left ventricle (*P ˂ 0.05). Conclusion: SDF-1/CXCR4 axis is affected in both ventricles of rats with monocrotaline model of pulmonary hypertension.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

单峰碱致肺动脉高压大鼠心室内SDF-1及其受体的变化

摘要目的：趋化因子-基质细胞衍生因子-1（SDF-1）在细胞凋亡、增殖、迁移和血管生成等过程中发挥重要作用，这些作用主要由受体CXCR4介导。本研究的目的是测定野百合碱诱导的肺动脉高压大鼠心室中SDF-1和CXCR4的表达。方法：10～12周龄雄性Wistar大鼠注射野百合碱（s.c.，60mg/kg；MON）或赋形剂（CON）。野百合碱给药后1周（1W-MON，1W-CON）、2周（2W-MON，2W-CON）和4周（4W-MON，4W-CON）处死大鼠。通过qRT-PCR测定SDF-1和CXCR4的基因表达。结果：在2W-MON和4W-MON大鼠中，SDF-1在右心室mRNA水平上的表达降低，而左心室没有任何变化；在1W-MON中，CXCR4在两心室的表达降低而在4W-MON中CXCR4表达增加（*P＜0.05）肺动脉高压模型。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

European Pharmaceutical Journal Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (all)

CiteScore

0.60

自引率

0.00%

发文量

期刊介绍： European Pharmaceutical Journal publishes only original articles not previously published and articles that are not being considered or have not been submitted for publication elsewhere. If parts of the results have been published as conference abstract or elsewhere, it should be stated in references. The ethical standards of the Helsinki-Tokio Declaration should be kept. This should be mentioned in the Methods of manuscript. Reviews are published only on request. Authors, whose submitted research work was performed with the support of a company, should indicate this in Conflict of Interest.